What is Xenetic Biosciences's market cap?

Xenetic Biosciences (XBIO) has a market capitalization of $5.7M and trades on NASDAQ.

Who are Xenetic Biosciences's competitors?

Xenetic Biosciences's key competitors include Merck & Co., Bristol-Myers Squibb, enGene Therapeutics Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Xenetic Biosciences partner with?

Xenetic Biosciences's notable partners include Takeda Pharmaceutical Co. Ltd., Scripps Research Institute, University of Virginia, and others.

What subsidiaries does Xenetic Biosciences have?

Xenetic Biosciences's subsidiaries include Hesperix S.A., Xenetic Biosciences (U.K.) Limited, Lipoxen Technologies Limited, and others.

Where is Xenetic Biosciences headquartered?

Xenetic Biosciences is headquartered in United States of America and employs approximately 4 people. It has been publicly traded since 2012.

Xenetic Biosciences

XBIO

Xenetic Biosciences is a biopharmaceutical company focused on developing innovative immuno-oncology technologies to treat difficult-to-address cancers.

Market cap

$5.73M+13.6%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$806.9K EPS-$0.20

Read the full report

Next report

Aug 7, 2026 (In 1 week)

Competitors

By market cap

Merck & Co.$322.95B+53.0%

Bristol-Myers Squibb$127.75B+32.1%

Immix Biopharma, Inc.$618.6M+716%

Benitec Biopharma Inc.$397.8M+37.5%

enGene Therapeutics Inc. $117.9M-36.6%

Boundless Bio, Inc.$55.7M+101%

Metagenomi Therapeutics, Inc. $45.6M-51.5%

Xenetic Biosciences$5.7M+2.0%

By revenue growth

Merck & Co.+2.9%

Bristol-Myers Squibb+1.8%

By net margin

Bristol-Myers Squibb15.01%+3.8pp

Merck & Co.13.59%-13.7pp

Profile

Xenetic Biosciences is a biopharmaceutical company focused on developing innovative immuno-oncology technologies to treat difficult-to-address cancers. The company's core value proposition centers on its proprietary DNase technology, which targets neutrophil extracellular traps (NETs) to improve the efficacy of existing treatments like immunotherapies, chemotherapies, and radiotherapies. By degrading the physical and immunosuppressive barriers created by NETs, the company aims to overcome treatment resistance in solid tumors.

Competitive position

An early-stage biopharmaceutical developer currently undergoing a strategic review to maximize shareholder value while advancing its DNase technology toward first-in-human clinical trials.

GeographiesUnited States, United Kingdom, Israel, Russia, India

Customer segmentsPharmaceutical manufacturers, Clinical research organizations

Business modelR&D focused, Licensing and Royalties, Collaborative Development

SuppliersContract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic research institutions, Specialized chemical and biological reagent suppliers

CustomersLarge pharmaceutical companies, Specialty biotechnology firms, Clinical trial sites and medical centers

CountryUnited States of America

Listed2012

Employees4.0

CEOJames F. Parslow

SectorHealthcare

IndustryBiotechnology

Websitexeneticbio.com

FilingsSEC EDGAR

Questions, answered.

What is Xenetic Biosciences's market cap?: Xenetic Biosciences (XBIO) has a market capitalization of $5.7M and trades on NASDAQ.
Who are Xenetic Biosciences's competitors?: Xenetic Biosciences's key competitors include Merck & Co., Bristol-Myers Squibb, enGene Therapeutics Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Xenetic Biosciences partner with?: Xenetic Biosciences's notable partners include Takeda Pharmaceutical Co. Ltd., Scripps Research Institute, University of Virginia, and others.
What subsidiaries does Xenetic Biosciences have?: Xenetic Biosciences's subsidiaries include Hesperix S.A., Xenetic Biosciences (U.K.) Limited, Lipoxen Technologies Limited, and others.
Where is Xenetic Biosciences headquartered?: Xenetic Biosciences is headquartered in United States of America and employs approximately 4 people. It has been publicly traded since 2012.